Alan Crowther and Jim Burke

Overview of EVERSANA's Value, Pricing, and Contracting services within the broader EVERSANA Commercial Vision, highlighting how these offerings are revolutionizing U.S. and global commercialization and their impact on Value, Pricing, and Contracting strategies.

Jim Burke, Mike Kurland, and Maria Eckley

Overview of the NAVLIN Revenue Management platform and roadmap for 2025, including case studies on maximizing the platform's value, coverage of direction, key enhancements, and roadmap items in 2025.

Alan Crowther and Chad Gibson

Understanding ex-U.S. pricing and market access for professionals with a primarily U.S.-focused background. This session explores key differences, major policy trends and shifts, and strategies for evaluating product potential in a global launch.

Jim Burke, Chad Gibson, and Mike Kurland

A comprehensive review of what the current landscape and likely policy changes will look like 90 days into the Trump administration, including the future of the IRA, ACA, 340B, and more.

Jay Seemann, BeiGene

Explore how a flexible and holistic approach to market access can help drive success in an increasingly complex and difficult access landscape in the U.S.

Andrew Hanhauser

NAVLIN Data is the gold standard for global drug pricing teams—now see how it elevates U.S. drug price and access analysis. Explore new features designed for U.S. pricing insights, access trends, and generic drug price evaluation.

Jim Burke and Kalderos

From initial contract negotiations through invoice processing, explore some of the key steps you can take to ensure all discounts are appropriate and not paid units acquired under the 340b program.

Alan Crowther and Kathleen Kulp

How to plan, forecast, and realize net revenue across all aspects from contracting to co-pay.

Chad Gibson and Brian Cotten

Take a look at how analytics are driving change in copay use and how the regulatory framework may aid or challenge firms efforts to assist patients.

Swami Subramanian, Regeneron

Exploring global gene therapy pricing and access and thinking about what it means for gene therapies in the pipeline.

Mike Kurland and Kathleen Kulp

Explore how data driven analytics-backed models enhance pricing strategies and demonstrate techniques for presenting insights effectively to pricing committees using backed evidence and scenario analysis.

Chad Gibson and Paul Voss, Rezolute

Leveraging AI and modeling to accelerate the assessment of orphan drug pricing and value, with insights into future trends in orphan drug pricing and access.

Maria Eckley

Roster data is often messy and difficult to align with company platforms - learn how to manage this process efficiently and gain more insights into your customer network structures.

Andrew Hanhauser

Explore how NAVLIN is advancing Pricing, Access and Contracting with GenAI to accelerate team productivity and generate faster data insights.

Chad Gibson

Chad Gibson will present on AI Direct-to-Patient and other future trends that will impact pricing.

An Evening with the Innovators at The Library St. Petersburg.

Omar Ali, Verpora and Ross Margulies, Manatt, Phelps & Phillips LLP, with facilitator Nick Merryfield, Verpora

Insights gained from the initial round of IRA negotiations by those who prepared and participated: an evaluation of effective and ineffective preparation methods, and anticipations for potential differences in future rounds.

Megan Seyboth

Impacts on manufacturer liabilities in the Part D space as the program transitions between the old and new structures

Alan Crowther

How to plan price & market access for a global launch - with a focus on critical considerations for smaller biopharma companies preparing for their first international release.

Jim Burke and client panel

Beyond just providing operational services, the RMS team is dedicated to ensuring our clients' success through valuable insights and consulting. Listen to your colleagues share how they've maximized their partnership with us.

Chad Gibson

How changes in IRA and global policies influence thinking about indication sequencing and strategies for planning.

Brian Cotten, Chad Gibson

An in-depth examination of analytical tools that can effectively facilitate PBM negotiations and how to leverage them to improve your success in contract negotiations.

Gary Watson

Overview of the roadmap and next-generation enhancements for NAVLIN's Global Pricing and Market Access software.

Patrick Beers and Stephanie Feher, Novo Nordisk

Gain insights from experts on effective strategies and execution in U.S. payer marketing, featuring an in-depth walkthrough of a successful case study.

Gary Watson and client panel

Strategies for implementing NAVLIN as a unified platform for pricing, market access, and contracting across the U.S. and global markets.

Nick Milazzo

Approaches to leveraging analogues in market access, pricing, and contracting, with case studies showcasing effective and innovative analogue analyses.

Chad Gibson and Alan Crowther

EU JCA is here for oncology products and coming in 2028 for orphan and rare disease. This covers the need to prepare for this now, as soon as the end of Phase II, even when commercial is still focused on US launch.

Mike Kurland and Brian Ushler

Navigating State Drug Price Transparency (SDPT) regulations is a critical aspect of a new product launch. This session will provide a detailed exploration of these requirements, spanning from pre-PDUFA stages to post-launch compliance.

Gustav Ando and Alan Crowther

Examining metrics and strategies for tracking and measuring the success of global launches, with insights tailored for both large and small biopharma companies. Discover how to transition from traditional tools like PowerPoint and Excel to advanced digital models for enhanced effectiveness.

Jim Burke

Engage in an interactive discussion on maximizing insights and leveraging the latest features of the NAVLIN Revenue Management platform.

Chad Gibson

An overview of U.S. and global pricing and contracting trends, with projections on payer expectations over the next five years.

Alan Crowther

Alan Crowther will present a US and Global perspective on how AI is - and isn't - changing Pricing and Market Access for the biopharma industry.

Conference closing remarks and customer award ceremony.